APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vaccine Particulate Adjuvants

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Vaccine Particulate Adjuvants Market Analysis and Forecast 2026-2032

26 December 2025199 pages

Choose your research edition.

Industry ResearchVaccine Particulate Adjuvants Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Vaccine Particulate Adjuvants Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Vaccine Particulate Adjuvants Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vaccine Particulate Adjuvants Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Vaccine Particulate Adjuvants Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Vaccine Particulate Adjuvants market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Vaccine Particulate Adjuvants is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Vaccine Particulate Adjuvants is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Vaccine Particulate Adjuvants is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Vaccine Particulate Adjuvants is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Vaccine Particulate Adjuvants include Agenus, Inc(US), Avanti Polar Lipids, Inc(US), Brenntag Biosector (Denmark), CSL Limited (Australia), Invivogen (US), MVP Laboratories, Inc(US), Novavax, Inc(US), OZ Biosciences (France) and SEPPIC (France), etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Vaccine Particulate Adjuvants, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Vaccine Particulate Adjuvants, also provides the sales of main regions and countries. Of the upcoming market potential for Vaccine Particulate Adjuvants, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Vaccine Particulate Adjuvants sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Vaccine Particulate Adjuvants market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Vaccine Particulate Adjuvants sales, projected growth trends, production technology, application and end-user industry.

Vaccine Particulate Adjuvants Segment by Company

Agenus, Inc(US)

Avanti Polar Lipids, Inc(US)

Brenntag Biosector (Denmark)

CSL Limited (Australia)

Invivogen (US)

MVP Laboratories, Inc(US)

Novavax, Inc(US)

OZ Biosciences (France)

SEPPIC (France)

SPI Pharma, Inc(US)

Vaccine Particulate Adjuvants Segment by Type

Subcutaneous

Intradermal

Oral

Intramuscular

Intranasal

Others

Vaccine Particulate Adjuvants Segment by Application

Infectious Diseases

Cancer

Others

Vaccine Particulate Adjuvants Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaccine Particulate Adjuvants market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vaccine Particulate Adjuvants and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaccine Particulate Adjuvants.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Vaccine Particulate Adjuvants in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Vaccine Particulate Adjuvants manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Vaccine Particulate Adjuvants sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Vaccine Particulate Adjuvants Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Subcutaneous Major Manufacturers Table 3. Intradermal Major Manufacturers Table 4. Oral Major Manufacturers Table 5. Intramuscular Major Manufacturers Table 6. Intranasal Major Manufacturers Table 7. Others Major Manufacturers Table 8. Global Vaccine Particulate Adjuvants Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Infectious Diseases Major Manufacturers Table 10. Cancer Major Manufacturers Table 11. Others Major Manufacturers Table 12. Vaccine Particulate Adjuvants Industry Trends Table 13. Vaccine Particulate Adjuvants Industry Drivers Table 14. Vaccine Particulate Adjuvants Industry Opportunities and Challenges Table 15. Vaccine Particulate Adjuvants Industry Restraints Table 16. Global Vaccine Particulate Adjuvants Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Vaccine Particulate Adjuvants Revenue by Region (2021-2026) & (US$ Million) Table 18. Global Vaccine Particulate Adjuvants Revenue by Region (2027-2032) & (US$ Million) Table 19. Global Vaccine Particulate Adjuvants Revenue Market Share by Region (2021-2026) Table 20. Global Vaccine Particulate Adjuvants Revenue Market Share by Region (2027-2032) Table 21. Global Vaccine Particulate Adjuvants Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (W Units) Table 22. Global Vaccine Particulate Adjuvants Sales by Region (2021-2026) & (W Units) Table 23. Global Vaccine Particulate Adjuvants Sales by Region (2027-2032) & (W Units) Table 24. Global Vaccine Particulate Adjuvants Sales Market Share by Region (2021-2026) Table 25. Global Vaccine Particulate Adjuvants Sales Market Share by Region (2027-2032) Table 26. Global Vaccine Particulate Adjuvants Revenue by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Vaccine Particulate Adjuvants Revenue Market Share by Manufacturers (2021-2026) Table 28. Global Vaccine Particulate Adjuvants Sales by Manufacturers (US$ Million) & (2021-2026) Table 29. Global Vaccine Particulate Adjuvants Sales Market Share by Manufacturers (2021-2026) Table 30. Global Vaccine Particulate Adjuvants Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 31. Global Vaccine Particulate Adjuvants Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 32. Global Vaccine Particulate Adjuvants Key Manufacturers Manufacturing Sites & Headquarters Table 33. Global Vaccine Particulate Adjuvants Manufacturers, Product Type & Application Table 34. Global Vaccine Particulate Adjuvants Manufacturers' Establishment Date Table 35. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 36. Global Vaccine Particulate Adjuvants by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 37. Global Vaccine Particulate Adjuvants Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Vaccine Particulate Adjuvants Revenue by Type (2021-2026) & (US$ Million) Table 39. Global Vaccine Particulate Adjuvants Revenue by Type (2027-2032) & (US$ Million) Table 40. Global Vaccine Particulate Adjuvants Revenue Market Share by Type (2021-2026) Table 41. Global Vaccine Particulate Adjuvants Revenue Market Share by Type (2027-2032) Table 42. Global Vaccine Particulate Adjuvants Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 43. Global Vaccine Particulate Adjuvants Sales by Type (2021-2026) & (W Units) Table 44. Global Vaccine Particulate Adjuvants Sales by Type (2027-2032) & (W Units) Table 45. Global Vaccine Particulate Adjuvants Sales Market Share by Type (2021-2026) Table 46. Global Vaccine Particulate Adjuvants Sales Market Share by Type (2027-2032) Table 47. Global Vaccine Particulate Adjuvants Price by Type (2021-2026) & (US$/Unit) Table 48. Global Vaccine Particulate Adjuvants Price by Type (2027-2032) & (US$/Unit) Table 49. Global Vaccine Particulate Adjuvants Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Vaccine Particulate Adjuvants Revenue by Application (2021-2026) & (US$ Million) Table 51. Global Vaccine Particulate Adjuvants Revenue by Application (2027-2032) & (US$ Million) Table 52. Global Vaccine Particulate Adjuvants Revenue Market Share by Application (2021-2026) Table 53. Global Vaccine Particulate Adjuvants Revenue Market Share by Application (2027-2032) Table 54. Global Vaccine Particulate Adjuvants Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 55. Global Vaccine Particulate Adjuvants Sales by Application (2021-2026) & (W Units) Table 56. Global Vaccine Particulate Adjuvants Sales by Application (2027-2032) & (W Units) Table 57. Global Vaccine Particulate Adjuvants Sales Market Share by Application (2021-2026) Table 58. Global Vaccine Particulate Adjuvants Sales Market Share by Application (2027-2032) Table 59. Global Vaccine Particulate Adjuvants Price by Application (2021-2026) & (US$/Unit) Table 60. Global Vaccine Particulate Adjuvants Price by Application (2027-2032) & (US$/Unit) Table 61. Agenus, Inc(US) Company Information Table 62. Agenus, Inc(US) Business Overview Table 63. Agenus, Inc(US) Vaccine Particulate Adjuvants Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. Agenus, Inc(US) Vaccine Particulate Adjuvants Product Portfolio Table 65. Agenus, Inc(US) Recent Development Table 66. Avanti Polar Lipids, Inc(US) Company Information Table 67. Avanti Polar Lipids, Inc(US) Business Overview Table 68. Avanti Polar Lipids, Inc(US) Vaccine Particulate Adjuvants Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Avanti Polar Lipids, Inc(US) Vaccine Particulate Adjuvants Product Portfolio Table 70. Avanti Polar Lipids, Inc(US) Recent Development Table 71. Brenntag Biosector (Denmark) Company Information Table 72. Brenntag Biosector (Denmark) Business Overview Table 73. Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Product Portfolio Table 75. Brenntag Biosector (Denmark) Recent Development Table 76. CSL Limited (Australia) Company Information Table 77. CSL Limited (Australia) Business Overview Table 78. CSL Limited (Australia) Vaccine Particulate Adjuvants Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. CSL Limited (Australia) Vaccine Particulate Adjuvants Product Portfolio Table 80. CSL Limited (Australia) Recent Development Table 81. Invivogen (US) Company Information Table 82. Invivogen (US) Business Overview Table 83. Invivogen (US) Vaccine Particulate Adjuvants Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Invivogen (US) Vaccine Particulate Adjuvants Product Portfolio Table 85. Invivogen (US) Recent Development Table 86. MVP Laboratories, Inc(US) Company Information Table 87. MVP Laboratories, Inc(US) Business Overview Table 88. MVP Laboratories, Inc(US) Vaccine Particulate Adjuvants Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. MVP Laboratories, Inc(US) Vaccine Particulate Adjuvants Product Portfolio Table 90. MVP Laboratories, Inc(US) Recent Development Table 91. Novavax, Inc(US) Company Information Table 92. Novavax, Inc(US) Business Overview Table 93. Novavax, Inc(US) Vaccine Particulate Adjuvants Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Novavax, Inc(US) Vaccine Particulate Adjuvants Product Portfolio Table 95. Novavax, Inc(US) Recent Development Table 96. OZ Biosciences (France) Company Information Table 97. OZ Biosciences (France) Business Overview Table 98. OZ Biosciences (France) Vaccine Particulate Adjuvants Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. OZ Biosciences (France) Vaccine Particulate Adjuvants Product Portfolio Table 100. OZ Biosciences (France) Recent Development Table 101. SEPPIC (France) Company Information Table 102. SEPPIC (France) Business Overview Table 103. SEPPIC (France) Vaccine Particulate Adjuvants Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. SEPPIC (France) Vaccine Particulate Adjuvants Product Portfolio Table 105. SEPPIC (France) Recent Development Table 106. SPI Pharma, Inc(US) Company Information Table 107. SPI Pharma, Inc(US) Business Overview Table 108. SPI Pharma, Inc(US) Vaccine Particulate Adjuvants Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. SPI Pharma, Inc(US) Vaccine Particulate Adjuvants Product Portfolio Table 110. SPI Pharma, Inc(US) Recent Development Table 111. North America Vaccine Particulate Adjuvants Revenue by Type (2021-2026) & (US$ Million) Table 112. North America Vaccine Particulate Adjuvants Revenue by Type (2027-2032) & (US$ Million) Table 113. North America Vaccine Particulate Adjuvants Sales by Type (2021-2026) & (W Units) Table 114. North America Vaccine Particulate Adjuvants Sales by Type (2027-2032) & (W Units) Table 115. North America Vaccine Particulate Adjuvants Sales Price by Type (2021-2026) & (US$/Unit) Table 116. North America Vaccine Particulate Adjuvants Sales Price by Type (2027-2032) & (US$/Unit) Table 117. North America Vaccine Particulate Adjuvants Revenue by Application (2021-2026) & (US$ Million) Table 118. North America Vaccine Particulate Adjuvants Revenue by Application (2027-2032) & (US$ Million) Table 119. North America Vaccine Particulate Adjuvants Sales by Application (2021-2026) & (W Units) Table 120. North America Vaccine Particulate Adjuvants Sales by Application (2027-2032) & (W Units) Table 121. North America Vaccine Particulate Adjuvants Sales Price by Application (2021-2026) & (US$/Unit) Table 122. North America Vaccine Particulate Adjuvants Sales Price by Application (2027-2032) & (US$/Unit) Table 123. North America Vaccine Particulate Adjuvants Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 124. North America Vaccine Particulate Adjuvants Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 125. North America Vaccine Particulate Adjuvants Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 126. North America Vaccine Particulate Adjuvants Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 127. North America Vaccine Particulate Adjuvants Sales by Country (2021-2026) & (W Units) Table 128. North America Vaccine Particulate Adjuvants Sales by Country (2027-2032) & (W Units) Table 129. North America Vaccine Particulate Adjuvants Sales Price by Country (2021-2026) & (US$/Unit) Table 130. North America Vaccine Particulate Adjuvants Sales Price by Country (2027-2032) & (US$/Unit) Table 131. United States Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 132. Canada Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 133. Mexico Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 134. Europe Vaccine Particulate Adjuvants Revenue by Type (2021-2026) & (US$ Million) Table 135. Europe Vaccine Particulate Adjuvants Revenue by Type (2027-2032) & (US$ Million) Table 136. Europe Vaccine Particulate Adjuvants Sales by Type (2021-2026) & (W Units) Table 137. Europe Vaccine Particulate Adjuvants Sales by Type (2027-2032) & (W Units) Table 138. Europe Vaccine Particulate Adjuvants Sales Price by Type (2021-2026) & (US$/Unit) Table 139. Europe Vaccine Particulate Adjuvants Sales Price by Type (2027-2032) & (US$/Unit) Table 140. Europe Vaccine Particulate Adjuvants Revenue by Application (2021-2026) & (US$ Million) Table 141. Europe Vaccine Particulate Adjuvants Revenue by Application (2027-2032) & (US$ Million) Table 142. Europe Vaccine Particulate Adjuvants Sales by Application (2021-2026) & (W Units) Table 143. Europe Vaccine Particulate Adjuvants Sales by Application (2027-2032) & (W Units) Table 144. Europe Vaccine Particulate Adjuvants Sales Price by Application (2021-2026) & (US$/Unit) Table 145. Europe Vaccine Particulate Adjuvants Sales Price by Application (2027-2032) & (US$/Unit) Table 146. Europe Vaccine Particulate Adjuvants Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 147. Europe Vaccine Particulate Adjuvants Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 148. Europe Vaccine Particulate Adjuvants Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 149. Europe Vaccine Particulate Adjuvants Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 150. Europe Vaccine Particulate Adjuvants Sales by Country (2021-2026) & (W Units) Table 151. Europe Vaccine Particulate Adjuvants Sales by Country (2027-2032) & (W Units) Table 152. Europe Vaccine Particulate Adjuvants Sales Price by Country (2021-2026) & (US$/Unit) Table 153. Europe Vaccine Particulate Adjuvants Sales Price by Country (2027-2032) & (US$/Unit) Table 154. Germany Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 155. France Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 156. U.K. Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 157. Italy Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 158. Russia Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 159. Spain Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 160. Netherlands Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 161. Switzerland Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 162. Sweden Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 163. Poland Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 164. China Vaccine Particulate Adjuvants Revenue by Type (2021-2026) & (US$ Million) Table 165. China Vaccine Particulate Adjuvants Revenue by Type (2027-2032) & (US$ Million) Table 166. China Vaccine Particulate Adjuvants Sales by Type (2021-2026) & (W Units) Table 167. China Vaccine Particulate Adjuvants Sales by Type (2027-2032) & (W Units) Table 168. China Vaccine Particulate Adjuvants Sales Price by Type (2021-2026) & (US$/Unit) Table 169. China Vaccine Particulate Adjuvants Sales Price by Type (2027-2032) & (US$/Unit) Table 170. China Vaccine Particulate Adjuvants Revenue by Application (2021-2026) & (US$ Million) Table 171. China Vaccine Particulate Adjuvants Revenue by Application (2027-2032) & (US$ Million) Table 172. China Vaccine Particulate Adjuvants Sales by Application (2021-2026) & (W Units) Table 173. China Vaccine Particulate Adjuvants Sales by Application (2027-2032) & (W Units) Table 174. China Vaccine Particulate Adjuvants Sales Price by Application (2021-2026) & (US$/Unit) Table 175. China Vaccine Particulate Adjuvants Sales Price by Application (2027-2032) & (US$/Unit) Table 176. Asia Vaccine Particulate Adjuvants Revenue by Type (2021-2026) & (US$ Million) Table 177. Asia Vaccine Particulate Adjuvants Revenue by Type (2027-2032) & (US$ Million) Table 178. Asia Vaccine Particulate Adjuvants Sales by Type (2021-2026) & (W Units) Table 179. Asia Vaccine Particulate Adjuvants Sales by Type (2027-2032) & (W Units) Table 180. Asia Vaccine Particulate Adjuvants Sales Price by Type (2021-2026) & (US$/Unit) Table 181. Asia Vaccine Particulate Adjuvants Sales Price by Type (2027-2032) & (US$/Unit) Table 182. Asia Vaccine Particulate Adjuvants Revenue by Application (2021-2026) & (US$ Million) Table 183. Asia Vaccine Particulate Adjuvants Revenue by Application (2027-2032) & (US$ Million) Table 184. Asia Vaccine Particulate Adjuvants Sales by Application (2021-2026) & (W Units) Table 185. Asia Vaccine Particulate Adjuvants Sales by Application (2027-2032) & (W Units) Table 186. Asia Vaccine Particulate Adjuvants Sales Price by Application (2021-2026) & (US$/Unit) Table 187. Asia Vaccine Particulate Adjuvants Sales Price by Application (2027-2032) & (US$/Unit) Table 188. Asia Vaccine Particulate Adjuvants Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 189. Asia Vaccine Particulate Adjuvants Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 190. Asia Vaccine Particulate Adjuvants Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 191. Asia Vaccine Particulate Adjuvants Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 192. Asia Vaccine Particulate Adjuvants Sales by Country (2021-2026) & (W Units) Table 193. Asia Vaccine Particulate Adjuvants Sales by Country (2027-2032) & (W Units) Table 194. Asia Vaccine Particulate Adjuvants Sales Price by Country (2021-2026) & (US$/Unit) Table 195. Asia Vaccine Particulate Adjuvants Sales Price by Country (2027-2032) & (US$/Unit) Table 196. Japan Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 197. South Korea Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 198. India Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 199. Australia Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 200. Taiwan Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 201. Southeast Asia Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 202. SAMEA Vaccine Particulate Adjuvants Revenue by Type (2021-2026) & (US$ Million) Table 203. SAMEA Vaccine Particulate Adjuvants Revenue by Type (2027-2032) & (US$ Million) Table 204. SAMEA Vaccine Particulate Adjuvants Sales by Type (2021-2026) & (W Units) Table 205. SAMEA Vaccine Particulate Adjuvants Sales by Type (2027-2032) & (W Units) Table 206. SAMEA Vaccine Particulate Adjuvants Sales Price by Type (2021-2026) & (US$/Unit) Table 207. SAMEA Vaccine Particulate Adjuvants Sales Price by Type (2027-2032) & (US$/Unit) Table 208. SAMEA Vaccine Particulate Adjuvants Revenue by Application (2021-2026) & (US$ Million) Table 209. SAMEA Vaccine Particulate Adjuvants Revenue by Application (2027-2032) & (US$ Million) Table 210. SAMEA Vaccine Particulate Adjuvants Sales by Application (2021-2026) & (W Units) Table 211. SAMEA Vaccine Particulate Adjuvants Sales by Application (2027-2032) & (W Units) Table 212. SAMEA Vaccine Particulate Adjuvants Sales Price by Application (2021-2026) & (US$/Unit) Table 213. SAMEA Vaccine Particulate Adjuvants Sales Price by Application (2027-2032) & (US$/Unit) Table 214. SAMEA Vaccine Particulate Adjuvants Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 215. SAMEA Vaccine Particulate Adjuvants Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 216. SAMEA Vaccine Particulate Adjuvants Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 217. SAMEA Vaccine Particulate Adjuvants Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 218. SAMEA Vaccine Particulate Adjuvants Sales by Country (2021-2026) & (W Units) Table 219. SAMEA Vaccine Particulate Adjuvants Sales by Country (2027-2032) & (W Units) Table 220. SAMEA Vaccine Particulate Adjuvants Sales Price by Country (2021-2026) & (US$/Unit) Table 221. SAMEA Vaccine Particulate Adjuvants Sales Price by Country (2027-2032) & (US$/Unit) Table 222. Brazil Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 223. Argentina Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 224. Chile Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 225. Colombia Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 226. Peru Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 227. Saudi Arabia Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 228. Israel Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 229. UAE Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 230. Turkey Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 231. Iran Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 232. Egypt Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Table 233. Key Raw Materials Table 234. Raw Materials Key Suppliers Table 235. Vaccine Particulate Adjuvants Distributors List Table 236. Vaccine Particulate Adjuvants Customers List Table 237. Research Programs/Design for This Report Table 238. Authors List of This Report Table 239. Secondary Sources Table 240. Primary Sources List of Figures Figure 1. Vaccine Particulate Adjuvants Image Figure 2. Global Vaccine Particulate Adjuvants Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vaccine Particulate Adjuvants Market Size Share 2021 VS 2025 VS 2032 Figure 4. Subcutaneous Image Figure 5. Intradermal Image Figure 6. Oral Image Figure 7. Intramuscular Image Figure 8. Intranasal Image Figure 9. Others Image Figure 10. Global Vaccine Particulate Adjuvants Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Vaccine Particulate Adjuvants Market Size Share 2021 VS 2025 VS 2032 Figure 12. Infectious Diseases Image Figure 13. Cancer Image Figure 14. Others Image Figure 15. Global Vaccine Particulate Adjuvants Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Figure 17. Global Vaccine Particulate Adjuvants Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Vaccine Particulate Adjuvants Revenue Market Share by Region: 2025 Versus 2032 Figure 19. Global Vaccine Particulate Adjuvants Revenue Market Share by Region (2021-2032) Figure 20. Global Vaccine Particulate Adjuvants Sales (2021-2032) & (W Units) Figure 21. Global Vaccine Particulate Adjuvants Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 22. Global Vaccine Particulate Adjuvants Sales Market Share by Region (2021-2032) Figure 23. US & Canada & Mexico Vaccine Particulate Adjuvants Sales YoY (2021-2032) & (W Units) Figure 24. Europe Vaccine Particulate Adjuvants Sales YoY (2021-2032) & (W Units) Figure 25. China Vaccine Particulate Adjuvants Sales YoY (2021-2032) & (W Units) Figure 26. Asia (Excluding China) Vaccine Particulate Adjuvants Sales YoY (2021-2032) & (W Units) Figure 27. South America, Middle East and Africa Vaccine Particulate Adjuvants Sales YoY (2021-2032) & (W Units) Figure 28. Global Vaccine Particulate Adjuvants Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 29. Global Vaccine Particulate Adjuvants Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 30. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Global Vaccine Particulate Adjuvants Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 32. Global Vaccine Particulate Adjuvants Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Vaccine Particulate Adjuvants Revenue Market Share by Type (2021-2032) Figure 34. Global Vaccine Particulate Adjuvants Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 35. Global Vaccine Particulate Adjuvants Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 36. Global Vaccine Particulate Adjuvants Sales Market Share by Type (2021-2032) Figure 37. Global Vaccine Particulate Adjuvants Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 38. Global Vaccine Particulate Adjuvants Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Vaccine Particulate Adjuvants Revenue Market Share by Application (2021-2032) Figure 40. Global Vaccine Particulate Adjuvants Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 41. Global Vaccine Particulate Adjuvants Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 42. Global Vaccine Particulate Adjuvants Sales Market Share by Application (2021-2032) Figure 43. North America Vaccine Particulate Adjuvants Revenue Share by Type (2021-2032) Figure 44. North America Vaccine Particulate Adjuvants Sales Share by Type (2021-2032) Figure 45. North America Vaccine Particulate Adjuvants Revenue Share by Application (2021-2032) Figure 46. North America Vaccine Particulate Adjuvants Sales Share by Application (2021-2032) Figure 47. North America Vaccine Particulate Adjuvants Revenue Share by Country (2021-2032) Figure 48. North America Vaccine Particulate Adjuvants Sales Share by Country (2021-2032) Figure 49. Europe Vaccine Particulate Adjuvants Revenue Share by Type (2021-2032) Figure 50. Europe Vaccine Particulate Adjuvants Sales Share by Type (2021-2032) Figure 51. Europe Vaccine Particulate Adjuvants Revenue Share by Application (2021-2032) Figure 52. Europe Vaccine Particulate Adjuvants Sales Share by Application (2021-2032) Figure 53. Europe Vaccine Particulate Adjuvants Revenue Share by Country (2021-2032) Figure 54. Europe Vaccine Particulate Adjuvants Sales Share by Country (2021-2032) Figure 55. China Vaccine Particulate Adjuvants Revenue Share by Type (2021-2032) Figure 56. China Vaccine Particulate Adjuvants Sales Share by Type (2021-2032) Figure 57. China Vaccine Particulate Adjuvants Revenue Share by Application (2021-2032) Figure 58. China Vaccine Particulate Adjuvants Sales Share by Application (2021-2032) Figure 59. Asia Vaccine Particulate Adjuvants Revenue Share by Type (2021-2032) Figure 60. Asia Vaccine Particulate Adjuvants Sales Share by Type (2021-2032) Figure 61. Asia Vaccine Particulate Adjuvants Revenue Share by Application (2021-2032) Figure 62. Asia Vaccine Particulate Adjuvants Sales Share by Application (2021-2032) Figure 63. Asia Vaccine Particulate Adjuvants Revenue Share by Country (2021-2032) Figure 64. Asia Vaccine Particulate Adjuvants Sales Share by Country (2021-2032) Figure 65. SAMEA Vaccine Particulate Adjuvants Revenue Share by Type (2021-2032) Figure 66. SAMEA Vaccine Particulate Adjuvants Sales Share by Type (2021-2032) Figure 67. SAMEA Vaccine Particulate Adjuvants Revenue Share by Application (2021-2032) Figure 68. SAMEA Vaccine Particulate Adjuvants Sales Share by Application (2021-2032) Figure 69. SAMEA Vaccine Particulate Adjuvants Revenue Share by Country (2021-2032) Figure 70. SAMEA Vaccine Particulate Adjuvants Sales Share by Country (2021-2032) Figure 71. Vaccine Particulate Adjuvants Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Vaccine Particulate Adjuvants Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Subcutaneous
  • Intradermal
  • Oral
  • Intramuscular
  • Intranasal
  • Others
Applications
  • Infectious Diseases
  • Cancer
  • Others
Companies covered
  • Agenus, Inc(US)
  • Avanti Polar Lipids, Inc(US)
  • Brenntag Biosector (Denmark)
  • CSL Limited (Australia)
  • Invivogen (US)
  • MVP Laboratories, Inc(US)
  • Novavax, Inc(US)
  • OZ Biosciences (France)
  • SEPPIC (France)
  • SPI Pharma, Inc(US)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Vaccine Particulate Adjuvants Market by Type
  3. 1.2.1 Global Vaccine Particulate Adjuvants Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Subcutaneous
  5. 1.2.3 Intradermal
  6. 1.2.4 Oral
  7. 1.2.5 Intramuscular
  8. 1.2.6 Intranasal
  9. 1.2.7 Others
  10. 1.3 Vaccine Particulate Adjuvants Market by Application
  11. 1.3.1 Global Vaccine Particulate Adjuvants Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Infectious Diseases
  13. 1.3.3 Cancer
  14. 1.3.4 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Vaccine Particulate Adjuvants Market Dynamics
  1. 2.1 Vaccine Particulate Adjuvants Industry Trends
  2. 2.2 Vaccine Particulate Adjuvants Industry Drivers
  3. 2.3 Vaccine Particulate Adjuvants Industry Opportunities and Challenges
  4. 2.4 Vaccine Particulate Adjuvants Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Vaccine Particulate Adjuvants Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Vaccine Particulate Adjuvants Revenue by Region
  3. 3.2.1 Global Vaccine Particulate Adjuvants Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Vaccine Particulate Adjuvants Revenue by Region (2021-2026)
  5. 3.2.3 Global Vaccine Particulate Adjuvants Revenue by Region (2027-2032)
  6. 3.2.4 Global Vaccine Particulate Adjuvants Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Vaccine Particulate Adjuvants Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Vaccine Particulate Adjuvants Sales by Region
  9. 3.4.1 Global Vaccine Particulate Adjuvants Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Vaccine Particulate Adjuvants Sales by Region (2021-2026)
  11. 3.4.3 Global Vaccine Particulate Adjuvants Sales by Region (2027-2032)
  12. 3.4.4 Global Vaccine Particulate Adjuvants Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Vaccine Particulate Adjuvants Revenue by Manufacturers
  2. 4.1.1 Global Vaccine Particulate Adjuvants Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Vaccine Particulate Adjuvants Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Vaccine Particulate Adjuvants Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Vaccine Particulate Adjuvants Sales by Manufacturers
  6. 4.2.1 Global Vaccine Particulate Adjuvants Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Vaccine Particulate Adjuvants Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Vaccine Particulate Adjuvants Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Vaccine Particulate Adjuvants Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Vaccine Particulate Adjuvants Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Vaccine Particulate Adjuvants Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Vaccine Particulate Adjuvants Manufacturers, Product Type & Application
  13. 4.7 Global Vaccine Particulate Adjuvants Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Vaccine Particulate Adjuvants Market CR5 and HHI
  16. 4.8.2 2025 Vaccine Particulate Adjuvants Tier 1, Tier 2, and Tier 3
5 Vaccine Particulate Adjuvants Market by Type
  1. 5.1 Global Vaccine Particulate Adjuvants Revenue by Type
  2. 5.1.1 Global Vaccine Particulate Adjuvants Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Vaccine Particulate Adjuvants Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Vaccine Particulate Adjuvants Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Vaccine Particulate Adjuvants Sales by Type
  6. 5.2.1 Global Vaccine Particulate Adjuvants Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Vaccine Particulate Adjuvants Sales by Type (2021-2032) & (W Units)
  8. 5.2.3 Global Vaccine Particulate Adjuvants Sales Market Share by Type (2021-2032)
  9. 5.3 Global Vaccine Particulate Adjuvants Price by Type
6 Vaccine Particulate Adjuvants Market by Application
  1. 6.1 Global Vaccine Particulate Adjuvants Revenue by Application
  2. 6.1.1 Global Vaccine Particulate Adjuvants Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Vaccine Particulate Adjuvants Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Vaccine Particulate Adjuvants Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Vaccine Particulate Adjuvants Sales by Application
  6. 6.2.1 Global Vaccine Particulate Adjuvants Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Vaccine Particulate Adjuvants Sales by Application (2021-2032) & (W Units)
  8. 6.2.3 Global Vaccine Particulate Adjuvants Sales Market Share by Application (2021-2032)
  9. 6.3 Global Vaccine Particulate Adjuvants Price by Application
7 Company Profiles
  1. 7.1 Agenus, Inc(US)
  2. 7.1.1 Agenus, Inc(US) Company Information
  3. 7.1.2 Agenus, Inc(US) Business Overview
  4. 7.1.3 Agenus, Inc(US) Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Agenus, Inc(US) Vaccine Particulate Adjuvants Product Portfolio
  6. 7.1.5 Agenus, Inc(US) Recent Developments
  7. 7.2 Avanti Polar Lipids, Inc(US)
  8. 7.2.1 Avanti Polar Lipids, Inc(US) Company Information
  9. 7.2.2 Avanti Polar Lipids, Inc(US) Business Overview
  10. 7.2.3 Avanti Polar Lipids, Inc(US) Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Avanti Polar Lipids, Inc(US) Vaccine Particulate Adjuvants Product Portfolio
  12. 7.2.5 Avanti Polar Lipids, Inc(US) Recent Developments
  13. 7.3 Brenntag Biosector (Denmark)
  14. 7.3.1 Brenntag Biosector (Denmark) Company Information
  15. 7.3.2 Brenntag Biosector (Denmark) Business Overview
  16. 7.3.3 Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Product Portfolio
  18. 7.3.5 Brenntag Biosector (Denmark) Recent Developments
  19. 7.4 CSL Limited (Australia)
  20. 7.4.1 CSL Limited (Australia) Company Information
  21. 7.4.2 CSL Limited (Australia) Business Overview
  22. 7.4.3 CSL Limited (Australia) Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 CSL Limited (Australia) Vaccine Particulate Adjuvants Product Portfolio
  24. 7.4.5 CSL Limited (Australia) Recent Developments
  25. 7.5 Invivogen (US)
  26. 7.5.1 Invivogen (US) Company Information
  27. 7.5.2 Invivogen (US) Business Overview
  28. 7.5.3 Invivogen (US) Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Invivogen (US) Vaccine Particulate Adjuvants Product Portfolio
  30. 7.5.5 Invivogen (US) Recent Developments
  31. 7.6 MVP Laboratories, Inc(US)
  32. 7.6.1 MVP Laboratories, Inc(US) Company Information
  33. 7.6.2 MVP Laboratories, Inc(US) Business Overview
  34. 7.6.3 MVP Laboratories, Inc(US) Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 MVP Laboratories, Inc(US) Vaccine Particulate Adjuvants Product Portfolio
  36. 7.6.5 MVP Laboratories, Inc(US) Recent Developments
  37. 7.7 Novavax, Inc(US)
  38. 7.7.1 Novavax, Inc(US) Company Information
  39. 7.7.2 Novavax, Inc(US) Business Overview
  40. 7.7.3 Novavax, Inc(US) Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Novavax, Inc(US) Vaccine Particulate Adjuvants Product Portfolio
  42. 7.7.5 Novavax, Inc(US) Recent Developments
  43. 7.8 OZ Biosciences (France)
  44. 7.8.1 OZ Biosciences (France) Company Information
  45. 7.8.2 OZ Biosciences (France) Business Overview
  46. 7.8.3 OZ Biosciences (France) Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 OZ Biosciences (France) Vaccine Particulate Adjuvants Product Portfolio
  48. 7.8.5 OZ Biosciences (France) Recent Developments
  49. 7.9 SEPPIC (France)
  50. 7.9.1 SEPPIC (France) Company Information
  51. 7.9.2 SEPPIC (France) Business Overview
  52. 7.9.3 SEPPIC (France) Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 SEPPIC (France) Vaccine Particulate Adjuvants Product Portfolio
  54. 7.9.5 SEPPIC (France) Recent Developments
  55. 7.10 SPI Pharma, Inc(US)
  56. 7.10.1 SPI Pharma, Inc(US) Company Information
  57. 7.10.2 SPI Pharma, Inc(US) Business Overview
  58. 7.10.3 SPI Pharma, Inc(US) Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 SPI Pharma, Inc(US) Vaccine Particulate Adjuvants Product Portfolio
  60. 7.10.5 SPI Pharma, Inc(US) Recent Developments
8 North America
  1. 8.1 North America Vaccine Particulate Adjuvants Market Size by Type
  2. 8.1.1 North America Vaccine Particulate Adjuvants Revenue by Type (2021-2032)
  3. 8.1.2 North America Vaccine Particulate Adjuvants Sales by Type (2021-2032)
  4. 8.1.3 North America Vaccine Particulate Adjuvants Price by Type (2021-2032)
  5. 8.2 North America Vaccine Particulate Adjuvants Market Size by Application
  6. 8.2.1 North America Vaccine Particulate Adjuvants Revenue by Application (2021-2032)
  7. 8.2.2 North America Vaccine Particulate Adjuvants Sales by Application (2021-2032)
  8. 8.2.3 North America Vaccine Particulate Adjuvants Price by Application (2021-2032)
  9. 8.3 North America Vaccine Particulate Adjuvants Market Size by Country
  10. 8.3.1 North America Vaccine Particulate Adjuvants Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Vaccine Particulate Adjuvants Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Vaccine Particulate Adjuvants Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Vaccine Particulate Adjuvants Market Size by Type
  2. 9.1.1 Europe Vaccine Particulate Adjuvants Revenue by Type (2021-2032)
  3. 9.1.2 Europe Vaccine Particulate Adjuvants Sales by Type (2021-2032)
  4. 9.1.3 Europe Vaccine Particulate Adjuvants Price by Type (2021-2032)
  5. 9.2 Europe Vaccine Particulate Adjuvants Market Size by Application
  6. 9.2.1 Europe Vaccine Particulate Adjuvants Revenue by Application (2021-2032)
  7. 9.2.2 Europe Vaccine Particulate Adjuvants Sales by Application (2021-2032)
  8. 9.2.3 Europe Vaccine Particulate Adjuvants Price by Application (2021-2032)
  9. 9.3 Europe Vaccine Particulate Adjuvants Market Size by Country
  10. 9.3.1 Europe Vaccine Particulate Adjuvants Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Vaccine Particulate Adjuvants Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Vaccine Particulate Adjuvants Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Vaccine Particulate Adjuvants Market Size by Type
  2. 10.1.1 China Vaccine Particulate Adjuvants Revenue by Type (2021-2032)
  3. 10.1.2 China Vaccine Particulate Adjuvants Sales by Type (2021-2032)
  4. 10.1.3 China Vaccine Particulate Adjuvants Price by Type (2021-2032)
  5. 10.2 China Vaccine Particulate Adjuvants Market Size by Application
  6. 10.2.1 China Vaccine Particulate Adjuvants Revenue by Application (2021-2032)
  7. 10.2.2 China Vaccine Particulate Adjuvants Sales by Application (2021-2032)
  8. 10.2.3 China Vaccine Particulate Adjuvants Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Vaccine Particulate Adjuvants Market Size by Type
  2. 11.1.1 Asia Vaccine Particulate Adjuvants Revenue by Type (2021-2032)
  3. 11.1.2 Asia Vaccine Particulate Adjuvants Sales by Type (2021-2032)
  4. 11.1.3 Asia Vaccine Particulate Adjuvants Price by Type (2021-2032)
  5. 11.2 Asia Vaccine Particulate Adjuvants Market Size by Application
  6. 11.2.1 Asia Vaccine Particulate Adjuvants Revenue by Application (2021-2032)
  7. 11.2.2 Asia Vaccine Particulate Adjuvants Sales by Application (2021-2032)
  8. 11.2.3 Asia Vaccine Particulate Adjuvants Price by Application (2021-2032)
  9. 11.3 Asia Vaccine Particulate Adjuvants Market Size by Country
  10. 11.3.1 Asia Vaccine Particulate Adjuvants Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Vaccine Particulate Adjuvants Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Vaccine Particulate Adjuvants Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Vaccine Particulate Adjuvants Market Size by Type
  2. 12.1.1 SAMEA Vaccine Particulate Adjuvants Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Vaccine Particulate Adjuvants Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Vaccine Particulate Adjuvants Price by Type (2021-2032)
  5. 12.2 SAMEA Vaccine Particulate Adjuvants Market Size by Application
  6. 12.2.1 SAMEA Vaccine Particulate Adjuvants Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Vaccine Particulate Adjuvants Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Vaccine Particulate Adjuvants Price by Application (2021-2032)
  9. 12.3 SAMEA Vaccine Particulate Adjuvants Market Size by Country
  10. 12.3.1 SAMEA Vaccine Particulate Adjuvants Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Vaccine Particulate Adjuvants Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Vaccine Particulate Adjuvants Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Vaccine Particulate Adjuvants Value Chain Analysis
  2. 13.1.1 Vaccine Particulate Adjuvants Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Vaccine Particulate Adjuvants Production Mode & Process
  6. 13.2 Vaccine Particulate Adjuvants Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Vaccine Particulate Adjuvants Distributors
  9. 13.2.3 Vaccine Particulate Adjuvants Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst